CRISPR/CRSP

$60.67

-3.56%
-
1D1W1MYTD1YMAX

About CRISPR

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Ticker

CRSP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Samarth Kulkarni

Employees

407

Headquarters

Zug, Switzerland

CRISPR Metrics

BasicAdvanced
$4.96B
Market cap
-
P/E ratio
-$1.95
EPS
1.76
Beta
-
Dividend rate
$4.96B
1.75525
$91.10
$37.55
1.84M
17.539
-6.87%
-8.17%
-7.24%
13.352
2.625
2.632
30,885.48%
76.72%
702.22%

What the Analysts think about CRISPR

Analyst Ratings

Majority rating from 29 analysts.
Buy

Price Targets

Average projection from 24 analysts.
41.47% upside
High $199.00
Low $30.00
$60.67
Current price
$85.83
Average price target

CRISPR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
44.38% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$201.2M
∞%
Net income
$89.3M
-179.66%
Profit margin
44.38%
∞%

CRISPR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 1,622.98%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.67
-$0.98
-$1.41
$1.10
-
Expected
-$1.70
-$2.12
-$1.95
-$0.07
-$1.41
Surprise
-60.66%
-53.72%
-27.72%
-1,622.98%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for CRISPR stock?

CRISPR (CRSP) has a market cap of $4.96B as of April 13, 2024.

What is the P/E ratio for CRISPR stock?

The price to earnings (P/E) ratio for CRISPR (CRSP) stock is 0 as of April 13, 2024.

Does CRISPR stock pay dividends?

No, CRISPR (CRSP) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next CRISPR dividend payment date?

CRISPR (CRSP) stock does not pay dividends to its shareholders.

What is the beta indicator for CRISPR?

CRISPR (CRSP) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the CRISPR stock price target?

The target price for CRISPR (CRSP) stock is $85.83, which is 41.47% above the current price of $60.67. This is an average based on projections from 24 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell CRISPR stock

Buy or sell CRISPR stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing